Tetsu Tanaka

Bio: Tetsu Tanaka is an academic researcher from Tohoku University. The author has contributed to research in topics: Wafer & Chip. The author has an hindex of 38, co-authored 406 publications receiving 10375 citations. Previous affiliations of Tetsu Tanaka include NTT DoCoMo & Tokyo Medical and Dental University.

Continuous Scaling Methodology of Planar CMOS Transistors by Suppressing Fluctuation in Carrier Profile

Abstract: The effects of an amorphous Si gate on various electrical fluctuations were evaluated for aggressively scaled CMOS transistors. After developing an advanced amorphous Si gate stack that effectively suppressed gate depletion, we measured intra-wafer fluctuations in gate capacitance and threshold voltage (Vth). The amorphous Si gate decreased intra-wafer fluctuations, intrinsic fluctuations of the scaled transistors, asymmetric fluctuation of the threshold voltage, and fluctuation in threshold voltage mismatch between neighboring transistors in the SRAM. Based on these results, we estimated a yield of the scaled SRAM for 45 nm technology node.

Enhancement of carrier mobility in metal-oxide semiconductor field-effect transistors using negative thermal expansion gate electrodes

Abstract: Strained-Si technology is crucial to improving the performance of metal-oxide-semiconductor field-effect transistors (MOSFETs). To introduce large strain into the channel, we proposed a structure for the negative thermal expansion gate electrode. In this study, we used manganese nitride as the gate material, which is a negative thermal expansion material. The fabricated MOSFETs with the manganese nitride gate showed a 10% increase in electron mobility compared to the MOSFET with the Al gate. The results show that the negative thermal expansion gate technology is promising as a technology booster for MOSFET scaling.

Development of Neural Probe with Microfluidic Channel Fabricated by using Wafer Direct Bonding Technique

Abstract: 1 Department of Biomedical Engineering, Graduate School of Biomedical Engineering, Tohoku University 6-6-01 Aza-Aoba, Aramaki, Aoba-ku, Sendai 980-8579, Japan Phone: +81-22-795-6906, Fax: +81-22-795-6907, E-mail: sdlab@sd.mech.tohoku.ac.jp 2 Department of Bioengineering and Robotics, Graduate School of Engineering, Tohoku University 3 Research Institute of Electrical Communication, Tohoku University 4 Department of Applied Information Science, Graduate School of Information Sciences, Tohoku University 5 Department of Physiology, Tohoku University School of Medicine

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

Abstract: Countless millions of people have died from tuberculosis, a chronic infectious disease caused by the tubercle bacillus. The complete genome sequence of the best-characterized strain of Mycobacterium tuberculosis, H37Rv, has been determined and analysed in order to improve our understanding of the biology of this slow-growing pathogen and to help the conception of new prophylactic and therapeutic interventions. The genome comprises 4,411,529 base pairs, contains around 4,000 genes, and has a very high guanine + cytosine content that is reflected in the biased amino-acid content of the proteins. M. tuberculosis differs radically from other bacteria in that a very large portion of its coding capacity is devoted to the production of enzymes involved in lipogenesis and lipolysis, and to two new families of glycine-rich proteins with a repetitive structure that may represent a source of antigenic variation.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Abstract: BackgroundExperimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. MethodsWe conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. ResultsAt 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in t...

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Abstract: Pseudomonas aeruginosa is a ubiquitous environmental bacterium that is one of the top three causes of opportunistic human infections. A major factor in its prominence as a pathogen is its intrinsic resistance to antibiotics and disinfectants. Here we report the complete sequence of P. aeruginosa strain PAO1. At 6.3 million base pairs, this is the largest bacterial genome sequenced, and the sequence provides insights into the basis of the versatility and intrinsic drug resistance of P. aeruginosa. Consistent with its larger genome size and environmental adaptability, P. aeruginosa contains the highest proportion of regulatory genes observed for a bacterial genome and a large number of genes involved in the catabolism, transport and efflux of organic compounds as well as four potential chemotaxis systems. We propose that the size and complexity of the P. aeruginosa genome reflect an evolutionary adaptation permitting it to thrive in diverse environments and resist the effects of a variety of antimicrobial substances.